Abivax (NASDAQ:ABVX) Reaches New 12-Month High – What’s Next?

Abivax SA Sponsored ADR (NASDAQ:ABVX) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $139.62 and last traded at $138.72, with a volume of 4152856 shares changing hands. The stock had previously closed at $114.94.

Analyst Ratings Changes

Several brokerages recently commented on ABVX. Wolfe Research upgraded shares of Abivax to a “strong-buy” rating in a report on Thursday, November 6th. Piper Sandler restated an “overweight” rating and issued a $142.00 price objective on shares of Abivax in a report on Tuesday, December 16th. Barclays assumed coverage on Abivax in a report on Monday, October 13th. They set an “overweight” rating and a $142.00 target price on the stock. Citigroup reissued an “outperform” rating on shares of Abivax in a research report on Tuesday, December 16th. Finally, BTIG Research boosted their price target on Abivax from $112.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Abivax presently has an average rating of “Moderate Buy” and an average price target of $128.73.

Abivax Price Performance

The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $11.54 billion, a price-to-earnings ratio of -85.62 and a beta of 0.48. The company’s 50 day moving average is $111.45 and its 200-day moving average is $74.67.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million during the quarter. Equities research analysts anticipate that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

Hedge Funds Weigh In On Abivax

Several institutional investors and hedge funds have recently modified their holdings of ABVX. EverSource Wealth Advisors LLC lifted its stake in shares of Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after buying an additional 369 shares during the last quarter. First Horizon Corp acquired a new stake in Abivax during the third quarter worth approximately $36,000. Bank of America Corp DE boosted its holdings in shares of Abivax by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after acquiring an additional 1,990 shares during the period. Hantz Financial Services Inc. acquired a new position in shares of Abivax in the third quarter valued at approximately $52,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after purchasing an additional 2,595 shares during the period. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.